R
Ribon Therapeutics
Ribon Therapeutics is pioneering the discovery and development of monoPARP inhibitors
About Ribon Therapeutics
Ribon Therapeutics is a clinical stage biopharmaceutical company that specializes in the development of novel small molecules targeting stress support pathways in cancer and inflammation. The company operates in the biotechnology and pharmaceutical market, serving clients such as hospitals, clinics, and other healthcare providers.
The company's business model revolves around its proprietary BEACON+ platform. This platform is designed to explore the biochemical roles of NAD+-utilizing enzymes and to discover and develop novel small molecule therapeutics. In simple terms, Ribon Therapeutics uses this platform to create new drugs that can target and disrupt the processes that cause cancer and inflammation.
One of the company's leading products is RBN-2397, a potent, selective, and orally available small molecule inhibitor of the monoPARP, PARP7. This drug is being developed for the treatment of solid tumors. The company has recently started a Phase 1 clinical study with another product, RBN-3143, in patients with moderate-to-severe atopic dermatitis.
Ribon Therapeutics generates revenue through the sale of its developed drugs to healthcare providers. The company also potentially earns income from partnerships with other pharmaceutical companies, research grants, and licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Cambridge, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 69.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2023 | $25M | $325M | Pfizer | ↗ |
| DEBTDebt | Apr 2022 | $50M | — | K2 HealthVentures | ↗ |
Growth signals
Latest recorded traffic for Ribon Therapeutics is 110 monthly website visits, down 83.6% over the last three months. Ribon Therapeutics's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ribon Therapeutics in the Cambridge ecosystem
The Ribon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
The Column Group
Osage University Partners
Novartis Venture Fund
Celgene
Deerfield
U.S. Venture Partners
Takeda Ventures
Johnson & Johnson Innovation- ECEuclidean Capital
Series B and later7 investors entered at this stage
Abbvie Biotech Ventures
Monashee Investment Management
Bristol-Myers Squibb
Peregrine Ventures- ACAvego Bioscience Capital
K2 HealthVentures
Pfizer
Other known investors3 additional known investors
Harvard University
Massachusetts Institute of Technology
UT Southwestern
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ribon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ribon Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








